Niti Aayog has launched a strategic plan to grow India's bioeconomy to $691 billion by 2035 through six national missions. The policy aims to boost manufacturing, research, and exports in healthcare and agriculture, with a proposed ₹50,000-crore investment fund. This shift focuses on reducing import reliance while supporting high-value job creation and commercializing domestic innovations.
Niti Aayog has unveiled a comprehensive strategic roadmap designed to transform India’s biotechnology sector. The plan aims to scale the nation's bioeconomy from approximately $195.3 billion to $691 billion over the next nine years. To achieve this, the proposal suggests moving away from fragmented departmental programs toward six mission-driven initiatives focused on practical, commercial outcomes.
Strategic Missions for Sector Growth
The six proposed missions are GeneIndia, which centers on gene and cell therapies; AgriBio 2.0, targeting climate-resilient crop development; BioX Foundry for synthetic biology commercialization; One Health Grid, an AI-powered disease surveillance network; a Marine Biotechnology mission for seaweed cultivation; and BioPharmaNext, which aims to strengthen India’s position in drug discovery and biologics. These areas are selected to bridge the gap between academic research and market-ready products, which has historically been a challenge for domestic biotech firms.
Investment and Policy Support
To drive this transition, the roadmap proposes an Empowered Committee and a National BioData Council to oversee implementation and regulatory coordination. A central component is the recommendation for a ₹50,000-crore BioEconomy Growth Fund to run from 2026 to 2035. This funding is intended to provide the necessary capital for scaling up manufacturing capabilities. Furthermore, the plan suggests introducing Production Linked Incentive (PLI) schemes specific to the sector, along with improved intellectual property protections to encourage companies to move toward higher-value product development.
Sector Context and Investor Perspective
India’s bioeconomy has grown significantly, increasing 16-fold over the last decade and currently contributing about 4.8% to the GDP. For investors, the long-term potential lies in the government's push to foster 15 globally competitive biotechnology companies. The success of this goal depends on several factors, including the actual deployment of the proposed growth fund, the speed of regulatory approvals, and the ability of domestic firms to compete with global leaders in biologics and drug discovery.
Investors should monitor how the government aligns these six missions with existing pharmaceutical and agricultural policies. The primary monitorable will be the establishment of the BioEconomy Investment and Policy Forum and the specific details of the proposed PLI-style incentives. Success in this sector will likely be defined by the ability to reduce import dependence on raw materials and specialized equipment, while expanding the scale of high-value manufacturing.